Kidney allograft transplantation improved the prognosis and quality of life of patients with end-stage renal diseases but the occurrence of acute rejection represents a limitation of the final outcome. Noninvasive biomarkers are needed as well as further advancements in the understanding of immune mechanisms of reaction to the allograft. Our study of 138 patients focused on one-year monitoring of serum concentrations of 12 chemokines regulating the recruitment of different immune cells into transplanted allograft and on in vitro regulation of the same chemokines release by interactions of renal proximal epithelial cells with monocyte/macrophage cell line stimulated with TNF alpha. In a group of 44 patients with acute rejection, higher serum pretransplant levels of CXCL1, CXCL5, CXCL6, CCL2, CCL21, and particularly CXCL10 and CX3CL1(both p < 0.001) were found suggesting their higher proinflammatory status as compared to subjects with the uncomplicated outcome. In samples collected at the day of biopsy positive for acute rejection, chemokines CXCL9 and CXCL11 attracting preferentially Th1 lymphocytes were found to be upregulated. In our in vitro model with TNF alpha induction, renal proximal epithelial cells seemed to be a more potent source of chemokines attracting neutrophils as compared to monocyte/macrophage cell line but the coculture of these cells potentiated release of neutrophilic chemokines CXCL5 and CXCL6. Similar augmentation of chemokine production was found also in the case of CCL2. On the other hand, adding of monocytes/macrophages to a culture of renal epithelial cells suppressed the release of CXCL10 and CXCL11 attracting T lymphocytes. We assume from our data that in kidney allograft transplantation, chemokines attracting neutrophils, T lymphocytes, and monocytes are induced simultaneously and measurement some of them in combination might be used as biomarkers of acute rejection. Mutual cell-cell interactions of immune cells with renal parenchyma seem to be important for fine regulation of chemokine release.

Department of Clinical and Transplant Immunology Institute for Clinical and Experimental Medicine Videnska 1958 9 Prague Czech Republic

Transplant Center Department of Nephrology Institute for Clinical and Experimental Medicine Videnska 1958 9 Prague Czech Republic

Zobrazit více v PubMed

Haas M., Loupy A., Lefaucheur C., et al. The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. American Journal of Transplantation. 2018;18(2):293–307. doi: 10.1111/ajt.14625. PubMed DOI PMC

Madill-Thomsen K., Perkowska-Ptasińska A., Böhmig G. A., et al. Discrepancy analysis comparing molecular and histology diagnoses in kidney transplant biopsies. American Journal of Transplantation. 2020;20(5):1341–1350. doi: 10.1111/ajt.15752. PubMed DOI

Eikmans M., Gielis E. M., Ledeganck K. J., Yang J., Abramowicz D., Claas F. F. J. Non-invasive biomarkers of acute rejection in kidney transplantation: novel targets and strategies. Frontiers in Medicine. 2019;5:p. 358. doi: 10.3389/fmed.2018.00358. PubMed DOI PMC

Ono S. J., Nakamura T., Miyazaki D., Ohbayashi M., Dawson M., Toda M. Chemokines: roles in leukocyte development, trafficking, and effector function. The Journal of Allergy and Clinical Immunology. 2003;111(6):1185–1199. doi: 10.1067/mai.2003.1594. PubMed DOI

Nomiyama H., Osada N., Yoshie O. Systematic classification of vertebrate chemokines based on conserved synteny and evolutionary history. Genes to Cells. 2013;18(1):1–16. doi: 10.1111/gtc.12013. PubMed DOI PMC

Blanchet X., Langer M., Weber C., Koenen R. R., von Hundelshausen P. Touch of chemokines. Frontiers in Immunology. 2012;3:p. 175. doi: 10.3389/fimmu.2012.00175. PubMed DOI PMC

Bachelerie F., Ben-Baruch A., Burkhardt A. M., et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacological Reviews. 2014;66(1):1–79. doi: 10.1124/pr.113.007724. PubMed DOI PMC

Dyer D. P., Medina-Ruiz L., Bartolini R., et al. Chemokine receptor redundancy and specificity are context dependent. Immunity. 2019;50(2):378–389.e5. doi: 10.1016/j.immuni.2019.01.009. e5. PubMed DOI PMC

Szabady R. L., McCormick B. A. Control of neutrophil inflammation at mucosal surfaces by secreted epithelial products. Frontiers in Immunology. 2013;4:p. 220. doi: 10.3389/fimmu.2013.00220. PubMed DOI PMC

Sanz M. J., Kubes P. Neutrophil-active chemokines in in vivo imaging of neutrophil trafficking. European Journal of Immunology. 2012;42(2):278–283. doi: 10.1002/eji.201142231. PubMed DOI

Thorburn Nee Krasna E., Kolesar L., Brabcova E., et al. CXC and CC chemokines induced in human renal epithelial cells by inflammatory cytokines. APMIS. 2009;117(7):477–487. doi: 10.1111/j.1600-0463.2009.02446.x. PubMed DOI

de Vries V. C., Elgueta R., Lee D. M., Noelle R. J. Mast cell protease 6 is required for allograft tolerance. Transplantation Proceedings. 2010;42(7):2759–2762. doi: 10.1016/j.transproceed.2010.05.168. PubMed DOI

Ascon M., Ascon D. B., Liu M., et al. Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes. Kidney International. 2009;75(5):526–535. doi: 10.1038/ki.2008.602. PubMed DOI PMC

Chen K., Bao Z., Tang P., Gong W., Yoshimura T., Wang J. M. Chemokines in homeostasis and diseases. Cellular & Molecular Immunology. 2018;15(4):324–334. doi: 10.1038/cmi.2017.134. PubMed DOI PMC

Ridiandries A., Tan J. T. M., Bursill C. The Role of Chemokines in Wound Healing. International Journal of Molecular Sciences. 2018;19(10):p. 3217. doi: 10.3390/ijms19103217. PubMed DOI PMC

Sahin H., Wasmuth H. E. Chemokines in tissue fibrosis. Biochimica et Biophysica Acta. 2013;1832(7):1041–1048. doi: 10.1016/j.bbadis.2012.11.004. PubMed DOI

Oghumu S., Nori U., Bracewell A., et al. Differential gene expression pattern in biopsies with renal allograft pyelonephritis and allograft rejection. Clinical Transplantation. 2016;30(9):1115–1133. doi: 10.1111/ctr.12795. PubMed DOI PMC

Bosshart H., Heinzelmann M. THP-1 cells as a model for human monocytes. Annals of Translational Medicine. 2016;4(21):p. 438. doi: 10.21037/atm.2016.08.53. PubMed DOI PMC

Rotondi M., Rosati A., Buonamano A., et al. High pretransplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure. American Journal of Transplantation. 2004;4(9):1466–1474. doi: 10.1111/j.1600-6143.2004.00525.x. PubMed DOI

Field M., Lowe D., Cobbold M., et al. The use of NGAL and IP-10 in the prediction of early acute rejection in highly sensitized patients following HLA-incompatible renal transplantation. Transplant International. 2014;27(4):362–370. doi: 10.1111/tri.12266. PubMed DOI

Matz M., Beyer J., Wunsch D., et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney International. 2006;69(9):1683–1690. doi: 10.1038/sj.ki.5000343. PubMed DOI

Ho J., Schaub S., Wiebe C., et al. Urinary CXCL10 chemokine is associated with alloimmune and virus compartment-specific renal allograft inflammation. Transplantation. 2018;102(3):521–529. doi: 10.1097/TP.0000000000001931. PubMed DOI

Mockler C., Sharma A., Gibson I. W., et al. The prognostic value of urinary chemokines at 6 months after pediatric kidney transplantation. Pediatric Transplantation. 2018;22(5, article e13205) doi: 10.1111/petr.13205. PubMed DOI

Malvezzi P., Fischman C., Rigault G., et al. Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol. Transplant Immunology. 2019;56:p. 101207. doi: 10.1016/j.trim.2019.04.002. PubMed DOI

Lo D. J., Weaver T. A., Kleiner D. E., et al. Chemokines and their receptors in human renal allotransplantation. Transplantation. 2011;91(1):70–77. doi: 10.1097/TP.0b013e3181fe12fc. PubMed DOI PMC

Li J., Koerner J., Basler M., Brunner T., Kirk C. J., Groettrup M. Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors. Kidney International. 2019;95(3):611–623. doi: 10.1016/j.kint.2018.10.022. PubMed DOI

Yun J. J., Fischbein M. P., Whiting D., et al. The role of MIG/CXCL9 in cardiac allograft vasculopathy. The American Journal of Pathology. 2002;161(4):1307–1313. doi: 10.1016/S0002-9440(10)64407-0. PubMed DOI PMC

Rotondi M., Netti G. S., Lazzeri E., et al. High pretransplant serum levels of CXCL9 are associated with increased risk of acute rejection and graft failure in kidney graft recipients. Transplant International. 2010;23(5):465–475. doi: 10.1111/j.1432-2277.2009.01006.x. PubMed DOI

Jones B., Koch A. E., Ahmed S. Pathological role of fractalkine/CX3CL1 in rheumatic diseases: a unique chemokine with multiple functions. Frontiers in Immunology. 2012;2:p. 82. doi: 10.3389/fimmu.2011.00082. PubMed DOI PMC

Xu C. X., Shi B. Y., Jin Z. K., et al. Multiple-biomarkers provide powerful prediction of early acute renal allograft rejection by combination of serum fractalkine, IFN-gamma and IP-10. Transplant Immunology. 2018;50:68–74. doi: 10.1016/j.trim.2018.08.003. PubMed DOI

Gerszten R. E., Garcia-Zepeda E. A., Lim Y. C., et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999;398(6729):718–723. doi: 10.1038/19546. PubMed DOI

Weber C., Belge K. U., von Hundelshausen P., et al. Differential chemokine receptor expression and function in human monocyte subpopulations. Journal of Leukocyte Biology. 2000;67(5):699–704. doi: 10.1002/jlb.67.5.699. PubMed DOI

Hribova P., Lacha J., Kotsch K., et al. Intrarenal cytokine and chemokine gene expression and kidney graft outcome. Kidney & Blood Pressure Research. 2007;30(5):273–282. doi: 10.1159/000105134. PubMed DOI

Pengam S., Durand J., Usal C., et al. SIRPalpha/CD47 axis controls the maintenance of transplant tolerance sustained by myeloid-derived suppressor cells. American Journal of Transplantation. 2019;19(12):3263–3275. doi: 10.1111/ajt.15497. PubMed DOI

Mueller F. B., Yang H., Lubetzky M., et al. Landscape of innate immune system transcriptome and acute T cell-mediated rejection of human kidney allografts. JCI Insight. 2019;4(13) doi: 10.1172/jci.insight.128014. PubMed DOI PMC

Mollica Poeta V., Massara M., Capucetti A., Bonecchi R. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Frontiers in Immunology. 2019;10:p. 379. doi: 10.3389/fimmu.2019.00379. PubMed DOI PMC

Hsu W. T., Lin C. H., Jui H. Y., et al. CXCR4 antagonist reduced the incidence of acute rejection and controlled cardiac allograft vasculopathy in a swine heart transplant model receiving a mycophenolate-based immunosuppressive regimen. Transplantation. 2018;102(12):2002–2011. doi: 10.1097/TP.0000000000002404. PubMed DOI PMC

Zou X. F., Gu J. H., Cui Z. L., Lu Y. W., Gu C. CXC chemokine receptor type 4 antagonism ameliorated allograft fibrosis in rat kidney transplant model. Experimental and Clinical Transplantation. 2017;15(4):448–452. doi: 10.6002/ect.2016.0071. PubMed DOI

Striz I. Cytokines of the IL-1 family: recognized targets in chronic inflammation underrated in organ transplantations. Clinical Science. 2017;131(17):2241–2256. doi: 10.1042/CS20170098. PubMed DOI